Quick Answer
RIGEL PHARMACEUTICALS INC reported Stockholders Equity of $391.48 million for the year ending 2025.
- RIGEL PHARMACEUTICALS INC showed an increase of +11,806.3% in Stockholders Equity from 2024 to 2025.
- This data is from RIGEL PHARMACEUTICALS INC's annual report (Form 10-K), filed with the SEC on March 3, 2026.
- XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2014: $188.33 million | Q2 2014: $165.73 million | Q3 2014: $146.85 million | Q1 2015: $112.15 million | Q2 2015: $101.15 million | Q3 2015: $96.41 million | Q1 2016: $75.45 million | Q2 2016: $73.72 million | Q3 2016: $65.94 million | Q1 2017: $84.08 million | Q2 2017: $69.61 million | Q3 2017: $56.17 million | Q1 2018: $79.81 million | Q2 2018: $123.57 million | Q3 2018: $103.47 million | Q1 2019: $95.32 million | Q2 2019: $78.29 million | Q3 2019: $68.91 million | Q1 2020: $78.50 million | Q2 2020: $63.21 million | Q3 2020: $50.96 million | Q1 2021: $78.30 million | Q2 2021: $68.11 million | Q3 2021: $49.67 million | Q1 2022: $6.80 million | Q2 2022: -$3.68 million | Q3 2022: -$19.83 million | Q1 2023: -$24.26 million | Q2 2023: -$28.12 million | Q3 2023: -$31.83 million | Q1 2024: -$31.67 million | Q2 2024: -$29.91 million | Q3 2024: -$14.64 million | Q1 2025: $18.57 million | Q2 2025: $81.93 million | Q3 2025: $117.61 million.
- Over the full 14 years of available data (2012 to 2025), RIGEL PHARMACEUTICALS INC's Stockholders Equity has grown by 35.4%.
- Historical annual values: Fiscal year 2025: $391.48 million | Fiscal year 2024: $3.29 million | Fiscal year 2023: -$28.64 million | Fiscal year 2022: -$13.62 million | Fiscal year 2021: $30.37 million | Fiscal year 2020: $34.03 million | Fiscal year 2019: $53.82 million | Fiscal year 2018: $109.88 million | Fiscal year 2017: $100.65 million | Fiscal year 2016: $55.03 million | Fiscal year 2015: $91.38 million | Fiscal year 2014: $128.25 million | Fiscal year 2013: $208.25 million | Fiscal year 2012: $289.10 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: